Lepu Medical: Interventional Multichannel Brain-Machine Interface Product Has Completed Animal Experimentation and Entered Human ITT Clinical Research Stage.

On April 22nd, Leap Medical announced at its performance briefing that the company has achieved a key breakthrough in the field of neural modulation technology and successfully obtained registration for implantable deep brain stimulation (DBS) systems. The company is currently fully committed to promoting the DBS market. The sales target for DBS this year is 1000 units, and 2-3 provinces have already completed network connections. The company is cautiously optimistic about the brain-machine interface industry. Brain-machine interfaces are divided into non-invasive and invasive categories. Non-invasive brain-machine interface products have already generated revenue, although the revenue contribution is currently small. The company is increasing its research and development efforts in non-invasive brain-machine interfaces that can complete brainwave perception analysis and intervention, and form closed-loop systems. Invasive multi-channel brain-machine interface products have completed animal experiments and have now entered the human ITT clinical research stage.